A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

Prior treatment

• Prior anti-cancer systemic therapy has been administered;
• Use of investigational drugs within 4 weeks；
• Received immunotherapy, macromolecular targeted therapy, or other antitumor biologics within 4 weeks; or received endocrine therapy, chemotherapy, small molecule targeted drug therapy, or traditional Chinese medicine treatment with antitumor indications within 2 weeks;
• Received radical radiotherapy within 4 weeks, or received palliative radiotherapy within 2 weeks;
• Previously received antitumor treatment or radiotherapy for any malignancy, excluding malignancies such as cured cervical carcinoma in situ, basal cell carcinoma, or squamous cell carcinoma;
• Prior anti-tumor treatment toxicities have not yet recovered to NCI CTCAE V5.0 grade ≤1 or baseline levels;
• Interstitial pneumonia/interstitial lung disease, or presence of moderate to severe pulmonary disease that may interfere with the detection or management of drug-related pulmonary toxicity within 3 months prior to the first administration of the study drug, as well as any autoimmune, connective tissue, or inflammatory diseases involving the lungs, or a history of total pulmonary resection surgery
• Inability to swallow, intestinal obstruction, or the presence of other factors affecting drug intake and absorption;
• According to the investigator's judgment, patients with severe concomitant diseases that pose a risk to their safety or prevent them from completing the study, a history of definite neurological or psychiatric disorders, including epilepsy or dementia, or any other condition deemed by the investigator to make the patient unsuitable for participation in this study.

Other illness

• Breast cancer that has not been histologically confirmed;
• Inflammatory breast cancer;
• Participants ineligible for endocrine therapy due to any disease burden, as judged by the investigator;
• Presence of diabetes symptoms, history of primary diabetes, gestational diabetes, steroid-induced diabetes, or other secondary diabetes;
• A history of other malignancies within the past 5 years, excluding cured cases of skin basal cell carcinoma and cervical carcinoma in situ;
• A history of immunodeficiency, including HIV positivity, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation;
• Presence of active hepatitis B, hepatitis C, liver cirrhosis, or severe infections requiring control with antibiotics, antiviral drugs, or antifungal medications;
• History of hereditary or acquired bleeding and thrombotic tendencies (such as haemophilia, coagulation disorders, etc.);
• Patients with known allergies or contraindications to the study drug and its excipient components;

Age

• Female patients who are pregnant or lactating, those of reproductive potential with a positive baseline pregnancy test, or those of reproductive age who are unwilling to use effective contraceptive measures throughout the entire study period;

Other

• Meningeal metastasis or active parenchymal brain metastasis;

• Female patients aged ≥18 years and ≤75 years;
• ECOG Performance Status of 0 -2;
• Locally advanced/metastatic breast cancer not amenable to curative therapy
• Disease progression during treatment or within 12 months of completing adjuvant therapy ;
• No prior anti-cancer systemic therapy has been administered;
• Fasting blood glucose \< 126 mg/dL, and HbA1C \< 6.0%;
• Life expectancy of ≥3 months;
• Patients have at least one target lesion according to RECEST 1.1;
• Adequate function of major organs;
• Female patients who are either premenopausal or have not undergone surgical sterilization: during the treatment period and for at least 7 months after the final dose of study medication, agree to abstain from sexual activity or utilize effective contraceptive methods.
• Sign Informed Consent Form.